Frederick T. Muto - Jun 15, 2021 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
Director
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Frederick T. Muto
Stock symbol
IONS
Transactions as of
Jun 15, 2021
Transactions value $
-$410,000
Form type
4
Date filed
6/17/2021, 05:05 PM
Next filing
Jul 6, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Options Exercise $46.5K +5K +15.78% $9.30* 36.7K Jun 15, 2021 Direct F1
transaction IONS Common Stock Sale -$183K -5K -13.63% $36.50 31.7K Jun 15, 2021 Direct F2
transaction IONS Common Stock Options Exercise $46.5K +5K +15.78% $9.30* 36.7K Jun 15, 2021 Direct F1
transaction IONS Common Stock Sale -$183K -5K -13.63% $36.55 31.7K Jun 15, 2021 Direct F2
transaction IONS Common Stock Options Exercise $46.5K +5K +15.78% $9.30* 36.7K Jun 15, 2021 Direct F1
transaction IONS Common Stock Sale -$184K -5K -13.63% $36.85 31.7K Jun 15, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -5K -33.33% $0.00 10K Jun 15, 2021 Common Stock 5K $9.30 Direct
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -5K -50% $0.00 5K Jun 15, 2021 Common Stock 5K $9.30 Direct
transaction IONS Non-Qualified Stock Option (right to buy) Options Exercise $0 -5K -100% $0.00* 0 Jun 15, 2021 Common Stock 5K $9.30 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquired as a result of exercising a stock option that was scheduled to expire on June 30, 2021. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020.
F2 Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on September 18, 2020.